Receive The Newest Study Notifications

I agree Seattle Genetics Announces Initiation of Phase 3 Clinical Trial of Tucatinib in Combination with Ado-trastuzumab Emtansine (T-DM1, Kadcyla®) for Patients with Advanced or Metastatic HER2-Positive Breast Cancer

by Lance Smith | Oct 10, 2019 | Study Scavenger Clinical Trial Recruitment Platform

BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq:SGEN) today announced dosing of the first patient in HER2CLIMB-02, a randomized phase 3 clinical trial evaluating investigational agent tucatinib versus placebo, in combination with...

Frequency Therapeutics Commences Dosing in its Phase 2a Study of FX-322 for Sensorineural Hearing Loss; FDA Grants FX-322 Fast Track Designation

by Lance Smith | Oct 10, 2019 | Study Scavenger Clinical Trial Recruitment Platform

WOBURN, Mass.–(BUSINESS WIRE)–Frequency Therapeutics (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that...

FDA Awards $2M to Phase 2 Trial of Vitamin D for Reducing Risk of SCD Respiratory Complications

by Lance Smith | Oct 10, 2019 | Study Scavenger Clinical Trial Recruitment Platform

The U.S. Food and Drug Administration (FDA) has awarded $2 million to support a Phase 2 clinical trial testing whether daily supplementation of vitamin D reduces the risk of respiratory complications in children and adolescents with sickle cell disease (SCD). Gary M....

Mustang Bio Announces City of Hope Receives $4.1 Million in Grant Awards for Recently Opened First-of-Its-Kind Clinical Trial for Patients with Recurrent Malignant Glioma

by Lance Smith | Oct 10, 2019 | Study Scavenger Clinical Trial Recruitment Platform

NEW YORK, Oct. 10, 2019 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors...

Penumbra Announces First Patient Enrolled in Study of Mechanical Power Aspiration for Thrombus Removal in Coronary Vessels

by Lance Smith | Oct 10, 2019 | Study Scavenger Clinical Trial Recruitment Platform

Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced enrollment of the first patient into the CHEETAH study, a prospective, multi-center U.S. study to evaluate the safety and performance of the Indigo System with CAT...

EyeGate Pharma Enrolls First Patient in Follow-on PE Pilot Study

by Lance Smith | Oct 10, 2019 | Study Scavenger Clinical Trial Recruitment Platform

WALTHAM, MA / ACCESSWIRE / October 9, 2019 / EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has enrolled the...